This website is intended for Ireland Healthcare Professionals only. Not a Healthcare Professional in Ireland? Click here
BETMIGA™ (mirabegron) logo

BetmigaTM (mirabegron) is indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome and for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to <18 years.1

How to initiate treatment

  • For adults (including elderly patients) with OAB, the recommended dose is 50 mg once daily. The tablet is to be taken with liquids, swallowed whole and is not to be chewed, divided, or crushed. It may be taken with or without food.1

  • For paediatric patients aged 3 to < 18 years with neurogenic detrusor overactivity, patients may be administered Betmiga prolonged-release tablets based on the body weight of the patient. The prolonged-release tablets may be administered to patients weighing 35 kg or more. The tablet is to be taken with food, swallowed whole, and is not to be chewed, divided, or crushed. The dose may be increased to a maximum dose of 50 mg once daily with food after 4 to 8 weeks if needed.1 For more information please click here.

References

  1. BETMIGA (mirabegron) prolonged-release tablets. Summary of Product Characteristics.

Adverse events should be reported. For Ireland, Healthcare professionals are asked to report any suspected adverse reactions via: HPRA Pharmacovigilance, Website: www.hpra.ie or Astellas Pharma Co. Ltd. Tel:+353 1 467 1555, E-mail: irishdrugsafety@astellas.com.

MAT-IE-BET-2026-00003 Sep 2026